The Course of Parosmia Improvement in Patients with COVID-19 in Iran
| Autor: | Hadi Jalilvand, Hesam Jahandideh, Doha Abo Aljadayel, Mojtaba Abdi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
lcsh:R5-920
Pediatrics medicine.medical_specialty parosmia Coronavirus disease 2019 (COVID-19) business.industry improvement process Parosmia taste disorder Triage 03 medical and health sciences 0302 clinical medicine covid-19 Cronbach's alpha Taste disorder Statistical significance Medicine In patient olfactory disorders 030212 general & internal medicine Family history medicine.symptom lcsh:Medicine (General) 030223 otorhinolaryngology business |
| Zdroj: | Taṣvīr-i salāmat, Vol 11, Iss 4, Pp 402-412 (2020) |
| ISSN: | 2423-6640 2008-9058 |
| Popis: | Background and Objectives: Smell disorder such as dostorted olfaction (parosmia) is one of the most common symptoms of COVID-19. Therefore, this study aimed to investigate the improvement of symptoms of parosmia in patients with COVID-19 in 2020. Material and Methods: This cross-sectional study was conducted in summer and spring of 2020 using a data collection form which was validated with Cronbach's alpha of r=0.826. The study was done in an international health center in Tehran. To report descriptive results, mean, standard deviation, absolute frequency and absolute frequency percentage, and for analysis, independent t-test and chi-square test were used using SPSS software version 16 and the significance level was considered to be 0.05. Results: In total ,350 patients participated in the study, the prevalence of parosmia in patients was 15.14% and the mean and age deviation of patients was 32.71 ± 10.93 years. There was not a significant relationship between parosmia and gender (p value=0.317), age (p value=0.271), previous history of allergic symptoms (p value=0.083), family history of the disease (p value=0.638), taste disorder (p-value=0.768), and smoking (p-value=0.558). 31 cases (58.49 % of Patients) with parosmia had complete remission within 4-6 weeks. Conclusion: Due to the high prevalence of olfactory disorders, especially parosmia in patients with COVID-19, parosmia and other olfactory disorders can be used to screen and triage patients with COVID-19, especially moderate and mild patients. Patients with parosmia should be followed for at least 4 to 6 weeks and if they do not recover for up to 12 weeks, they should be referred to ENT specialists for more specific measures. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|